



Newstar Medical Laboratories - Atlanta

975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144

Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553

Laboratory Director : Chesie Voma

PATIENT

DEMOGRAPHICS

Patient Name: PATRICIA KIKER	Account: The Doleys Clinic	Order Code: NE22-0004752
DOB: 08/14/1948	Provider: Christopher Hill	Sample Type: Urine
Patient Gender: F	Accession: 22022400048	Collected: 02/23/2022
Patient Phone Number: (205) 275-7141	Report Status:	Received: 2022-02-24T16:44:54.878871
		Reported: 04/04/2022

PRESCRIPTION

LIST

Oxycodone (OXY , Percocet , Endocet , Percodan , Percolone , Roxicodone , Tylox)	Z79.891, Z79.899
--	------------------

INCONSISTENT			
NOT PRESCRIBED		DETECTED	
Class	Test	Cutoff (ng/mL)	Results (ng/mL)
SEDATIVE	Alprazolam	30	570.67
	[DDI] The risk or severity of adverse effects can be increased when Oxycodone is combined with Alprazolam. The risk or severity of adverse effects can be increased when Oxymorphone is combined with Alprazolam.		
SEDATIVE	alpha-Hydroxyalprazolam	30	1191.35
	Metabolite of Alprazolam		
	Zolpidem	10	105.68
	[DDI] Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.		
SEDATIVE	Carboxyzolpidem	10	> 2500
	Metabolite of Zolpidem		
NSAID	Acetaminophen	400	102929.55
	[DDI] The metabolism of Oxymorphone can be decreased when combined with Acetaminophen. The metabolism of Alprazolam can be decreased when combined with Acetaminophen. The metabolism of Zolpidem can be increased when combined with Acetaminophen.		

INCONSISTENT		
PRESCRIBED		NOT DETECTED
Class	Test	Cutoff (ng/mL)
		"NO RESULTS"

CONTRAINDICATION		NOT TESTED
Drug	Contraindication	
		"NO RESULTS"

CONSISTENT			
PRESCRIBED		DETECTED	
Class	Test	Cutoff (ng/mL)	Results (ng/mL)
OPIOID	Oxycodone	400	1411.18
	[DDI] The risk or severity of adverse effects can be increased when Oxycodone is combined with Oxymorphone.		
OPIOID	Noroxycodone	400	2163.05
	Metabolite of Oxycodone		
OPIOID	Oxymorphone	400	3096.24
	Metabolite of Oxycodone		
	Noroxymorphone	400	954.84

VALIDITY TESTING & SCREENS		
Specimen Validity	Range	Results
PH	4.50 - 8.00	5.2
Specific Gravity	1.01 - 1.03	1.01
Urine Creatinine (mg/dL)	20.00 - 400.00	147.9



Newstar Medical Laboratories - Atlanta
975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144
Phone: (678) 505-8016 | Fax:(678) 806-7192
CLIA ID: 11D2145553
Laboratory Director : Chesie Voma

PATIENT
DEMOGRAPHICS

Patient Name: PATRICIA KIKER	Account: The Doleys Clinic	Order Code: NE22-0004752
DOB: 08/14/1948	Provider: Christopher Hill	Sample Type: Urine
Patient Gender: F	Accession: 22022400048	Collected: 02/23/2022
Patient Phone Number: (205) 275-7141	Report Status:	Received: 2022-02-24T16:44:54.878871
		Reported: 04/04/2022

NOT PRESCRIBED				NOT DETECTED	
Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)
6-MAM		Ethyl Sulfate		Oxazepam	
7-Aminoclonazepam		Alpha-PVP			
Butalbital		AM2201 Hydroxypentyl			
Hydrochlorothiazide		Amitriptyline			
Ketamine		Amphetamine			
Lorazepam		Atomoxetine			
MDA		Benzoylcegonine			
MDMA		Buprenorphine			
Meperidine		Bupropion			
Mephedrone		Carisoprodol			
Meprobamate		Paroxetine			
Metformin		Phencyclidine			
Methadone		Phentermine			
Methamphetamine		Pregabalin			
Methylone		Propoxyphene			
Methylphenidate		Quetiapine			
Midazolam		Ritalinic Acid			
Naloxone		Sertraline			
Naltrexone		Tapentadol			
N-Desmethylcitalopram		Temazepam			
Norbuprenorphine		Tramadol			
Nordiazepam		Trazodone			
Norfentanyl		Triazolam			
Norhydrocodone		UR-144 Hydroxypentyl			
Norhydromorphone		Venlafaxine			
Norketamine		XLR-11 Hydroxypentyl			
Phenobarbital		Citalopram			
Salicylic Acid		Clonazepam			
THC-COOH		Codeine			
Ethyl Glucuronide		Cotinine			

IMPORTANT DISCLAIMER NOTICE : Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.